Brief: Philogen Announces Enrolment Of 214 Patients In The Nidlegy™ Phase III European Clinical Trial For The Treatment Of Locally Advanced Melanoma
25/07/2022 14:30
July 25 (Reuters) - Philogen SpA PHIL.MI :
* PHILOGEN ANNOUNCES ENROLMENT OF 214 PATIENTS IN THE
NIDLEGY™
PHASE III EUROPEAN CLINICAL TRIAL FOR THE TREATMENT OF LOCALLY
ADVANCED MELANOMA
Source text for Eikon: ID:nGNX3ZntQM
Further company coverage: PHIL.MI
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Philogen
See all newsBrief: Philogen H1 Net Loss €19.6 Mln
Brief: Philogen Resubmits To EMA Marketing Authorization Application For Nidlegy
Brief: Sun Pharma Says Partner Philogen's Phase II Flash Study In Soft Tissue Sarcoma Did Not Meet Primary Endpoint
Brief: Philogen Reports FY EBITDA Of EUR 261.6 Million
Brief: Philogen H1 Net Loss EUR 14,894